BioGX Celebrates Success Of Global Partnership Initiative, Announces New Distribution Partnerships In EMEA And Asia-Pacific

Amsterdam, The Netherlands, 01 November 2018 – Amsterdam-based BioGX B.V., a subsidiary of Birmingham, Alabama based molecular diagnostics company BioGX, today announced several new distribution partnerships in the EMEA and Asia-Pacific as it continues to expand its global presence. Read more

BioGX Launches 5 New CE Mark IVD Tests, Expands Number Of Sexual Health Panels

Amsterdam, The Netherlands, 23 October 2018 – BioGX B.V. recently released 5 new sexual health CE Mark IVD tests, expanding BioGX’s CE-IVD menu to a total of 21 multiplex panels, with additional test panels to be released before the end of 2018. Read more

BioGX Launches Six CE-Mark Tests For Meningitis And Antibiotic Resistance

Amsterdam, The Netherlands, 24 May 2018 – BioGX B.V. continues its *BD MAX menu expansion with the launch of six additional CE-Mark infectious disease tests on Becton, Dickinson and Company’s BD MAX Sample-to-Answer platform. This brings the company’s CE-Mark menu for the BD MAX to eleven tests, with an additional ten planned for the second half of 2018. Read more

BioGX And Launch Diagnostics Announce Distribution Partnership For U.K. And Ireland

BIRMINGHAM, Ala., Feb. 8, 2018 /PRNewswire/ — BioGX continues to expand its global presence with the announcement of a distribution partnership between BioGX’s Amsterdam-based European subsidiary, BioGX B.V., and U.K.-based distributor, Launch Diagnostics. Read more

BioGX BV And AxonLab AG Announce Distribution Partnership

BIRMINGHAM, Ala., Feb. 6, 2018 /PRNewswire/ — BioGX continues to expand its international presence with the announcement of a new strategic partnership between BioGX’s Amsterdam-based European subsidiary and Switzerland-based distributor, AxonLab AG. Read more

BioGX Launches Four CE-Marked IVD Assays At The European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

VIENNA, AUSTRIA, April 24, 2017 /PRNewswire/ — BioGX, a Birmingham Alabama based molecular diagnostics company, announced the launch of four additional CE-IVD infectious disease tests at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), reflecting the inspiring vision of ECCMID: “Managing Infections, Promoting Science”. BioGX has developed an extensive line of multiplex tests for infectious organisms that aid in early diagnosis and proactive management of infections. Read more

Announcing The Establishment Of BioGX EU

BIRMINGHAM, Ala., April 21, 2017 /PRNewswire/ — BioGX, a developer and manufacturer of molecular diagnostics CE-IVD tests has announced the establishment of European operations based in Amsterdam, Netherlands.

BioGX Sample-Ready™ Technology Selected By NASA For Genetic Analysis Aboard The International Space Station

BIRMINGHAM, Ala., November 10, 2016 — BioGX announced its Sample-Ready™ lyophilized qPCR technology was selected by the NASA WetLab-2 program to conduct genetic analysis aboard the International Space Station (ISS). BioGX core technology enables real-time PCR based scientific studies in the microgravity environment of the ISS. Read more

BioGX Receives CE-IVD Mark For Influenza A, B And Respiratory Syncytial Virus Assay On The BD MAX System

BioGX announced it has received CE-IVD marking for its Flu A, Flu B, RSV automated test on Becton, Dickinson and Company’s (BD) BD MAXTM system for detection of Influenza A, B and Respiratory Syncytial Virus (RSV). The test is intended to simultaneously detect the presence of Flu A, Flu B and RSV RNA present in nasopharyngeal swabs samples collected from individuals at risk of infection. Read more